Strides Arcolab

This page shows the latest Strides Arcolab news and features for those working in and with pharma, biotech and healthcare.

India turns down patent on Gilead's Sovaldi

Cipla, Cadila Healthcare, Hetero, Strides Arcolab, Ranbaxy, Sequent Scientific and Mylan) at a 7% royalty rate.

Sovaldi deal for developing world ‘falls short’

Strides Arcolab - include some of the world's largest generic players, reports the Pharmalot blog.
Pfizer inks $360m deal to buy InnoPharma

Last year, generics giant Mylan made a big leap forward in the sector with a $1.6bn agreement to buy Strides Arcolab's sterile injectables unit Agila, while Becton Dickinson has
Hikma to retain injectables unit

Hikma said in March it decided to look into the future of the division after being sent unsolicited offers in the wake of Mylan's $1.6bn deal to acquire Strides ... Arcolab's injectables unit.
Injectables land-grab set to continue as Hikma reports offers

Hikma has said it is looking into the future of its injectable drugs unit after overtures from possible buyers, just days after Mylan agreed a $1.6bn deal to buy Strides ... Mylan said when it announced its deal for Strides Arcolab's Agila unit that it
Mylan agrees $1.6bn deal to buy Agila injectables unit

Consolidation continues apace in the generics sector, with Mylan agreeing a $1.6bn deal to acquire Strides Arcolab of India's sterile injectables business unit.

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Pharma deals in May 2015

360. Aspen/ Strides Arcolab. Divestment. Range of branded and generic drugs.
Deal Watch table for September 2014

200. Shasun / Strides Arcolab. Company acquisition. Shasun is an Indian API and generic company.
Pharma deals during September 2014

year. In India this month, Strides Arcolab has acquired another Indian generic and API supplier Shasun in an all stock deal worth $200m to add products to its portfolio.
The rise of chronic disease in BRIC markets

with Strides Arcolab to jointly manufacture and distribute generic cancer drugs in developing markets.
Pharma deals during February 2013

In the largest, it announced its planned acquisition of Strides Arcolab's subsidiary, Agila Specialities for a total of $1.85bn.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Principal Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Add my company

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....